What is your preferred third-line therapy for metastatic colon cancer, RAS-WT, MSS, low TMB, with no targetable alterations?

My preferred treatment in this scenario is trifluridine-tipiracil plus bevacizumab. This is based on the favorable side-effect profile of this regimen (compared to alternatives) and the evidence from the SUNLIGHT trial, which showed that bevacizumab plus trifluridine-tipiracil was superior to triflu...